Natural history of noninfectious, ibrutinib-attributable adverse events in patients with chronic lymphocytic leukemia

被引：1
|
作者：
Khountham, Soun [1 ]
Shindiapina, Polina [1 ]
Mo, Xiaokui [2 ]
Lachowiez, Curtis [3 ]
Wiczer, Tracy [4 ]
Mousa, Luay [1 ]
Rogers, Kerry A. [1 ]
Andritsos, Leslie A. [1 ]
Woyach, Jennifer A. [1 ]
Byrd, John C. [1 ]
Spurgeon, Stephen E. [3 ]
Awan, Farrukh T. [5 ]
机构：
[1] Ohio State Univ, Ctr Comprehens Canc, Dept Internal Med, Div Hematol, Columbus, OH 43210 USA
[2] Ohio State Univ, Ctr Biostat, Columbus, OH 43210 USA
[3] Oregon Hlth & Sci Univ, Div Hematol & Med Oncol, Portland, OR 97201 USA
[4] Ohio State Univ, Ctr Comprehens Canc, Dept Pharm, Columbus, OH 43210 USA
[5] Univ Texas Southwestern Med Ctr Dallas, Div Hematol & Med Oncol, Dallas, TX 75390 USA
来源：
LEUKEMIA & LYMPHOMA | 2021年 / 62卷 / 03期
关键词：
ATRIAL-FIBRILLATION; OUTCOMES; THERAPY;
D O I：
10.1080/10428194.2020.1838508
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：716 / 721
页数：6
相关论文
共 50 条
  • [1] Keeping a balance in chronic lymphocytic leukemia (CLL) patients taking ibrutinib: ibrutinib-associated adverse events and their management based on drug interactions
    Cho, Hee Jeong
    Baek, Dong Won
    Kim, Juhyung
    Lee, Jung Min
    Moon, Joon Ho
    Sohn, Sang Kyun
    EXPERT REVIEW OF HEMATOLOGY, 2021, 14 (09) : 819 - 830
  • [2] Ibrutinib for Chronic Lymphocytic Leukemia
    Sharman, Jeff P.
    Mato, Anthony R.
    Keating, Michael J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2016, 374 (16): : 1592 - 1593
  • [3] A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia
    Chen, Lisa S.
    Bose, Prithviraj
    Cruz, Nichole D.
    Jiang, Yongying
    Wu, Qi
    Thompson, Philip A.
    Feng, Shuju
    Kroll, Michael H.
    Qiao, Wei
    Huang, Xuelin
    Jain, Nitin
    Wierda, William G.
    Keating, Michael J.
    Gandhi, Varsha
    BLOOD, 2018, 132 (21) : 2249 - 2259
  • [4] Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib
    Awan, Farrukh T.
    Schuh, Anna
    Brown, Jennifer R.
    Furman, Richard R.
    Pagel, John M.
    Hillmen, Peter
    Stephens, Deborah M.
    Woyach, Jennifer
    Bibikova, Elena
    Charuworn, Prista
    Frigault, Melanie M.
    Hamdy, Ahmed
    Izumi, Raquel
    Linghu, Bolan
    Patel, Priti
    Wang, Min Hui
    Byrd, John C.
    BLOOD ADVANCES, 2019, 3 (09) : 1553 - 1562
  • [5] Ibrutinib for the treatment of chronic lymphocytic leukemia
    Deodato, Marina
    Frustaci, Anna Maria
    Zamprogna, Giulia
    Cairoli, Roberto
    Montillo, Marco
    Tedeschi, Alessandra
    EXPERT REVIEW OF HEMATOLOGY, 2019, 12 (05) : 273 - 284
  • [6] How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia
    Stephens, Deborah M.
    Byrd, John C.
    BLOOD, 2019, 133 (12) : 1298 - 1307
  • [7] Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia
    Burger, Jan A.
    Sivina, Mariela
    Jain, Nitin
    Kim, Ekaterina
    Kadia, Tapan
    Estrov, Zeev
    Nogueras-Gonzalez, Graciela M.
    Huang, Xuelin
    Jorgensen, Jeffrey
    Li, Jianling
    Cheng, Mei
    Clow, Fong
    Ohanian, Maro
    Andreeff, Michael
    Mathew, Thomas
    Thompson, Philip
    Kantarjian, Hagop
    O'Brien, Susan
    Wierda, William G.
    Ferrajoli, Alessandra
    Keating, Michael J.
    BLOOD, 2019, 133 (10) : 1011 - 1019
  • [8] Adverse drug events associated with ibrutinib for the treatment of elderly patients with chronic lymphocytic leukemia A systematic review and meta-analysis of randomized trials
    Zhou, Yanhua
    Lu, Hongtao
    Yang, Meifeng
    Xu, Chenhong
    MEDICINE, 2019, 98 (33)
  • [9] Overcoming Ibrutinib Resistance in Chronic Lymphocytic Leukemia
    Pula, Bartosz
    Golos, Aleksandra
    Gorniak, Patryk
    Jamroziak, Krzysztof
    CANCERS, 2019, 11 (12)
  • [10] The clinical safety of ibrutinib in chronic lymphocytic leukemia
    Molica, Stefano
    EXPERT OPINION ON DRUG SAFETY, 2015, 14 (10) : 1621 - 1629
12345